Historical Valuation
Corcept Therapeutics Inc (CORT) is now in the Overvalued zone, suggesting that its current forward PE ratio of 71.90 is considered Overvalued compared with the five-year average of 34.86. The fair price of Corcept Therapeutics Inc (CORT) is between 9.86 to 28.86 according to relative valuation methord. Compared to the current price of 36.74 USD , Corcept Therapeutics Inc is Overvalued By 27.29%.
Relative Value
Fair Zone
9.86-28.86
Current Price：36.74
27.29%
Overvalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Corcept Therapeutics Inc (CORT) has a current Price-to-Book (P/B) ratio of 6.35. Compared to its 3-year average P/B ratio of 7.80 , the current P/B ratio is approximately -18.48% higher. Relative to its 5-year average P/B ratio of 6.85, the current P/B ratio is about -7.22% higher. Corcept Therapeutics Inc (CORT) has a Forward Free Cash Flow (FCF) yield of approximately 4.06%. Compared to its 3-year average FCF yield of 3.74%, the current FCF yield is approximately 8.48% lower. Relative to its 5-year average FCF yield of 4.67% , the current FCF yield is about -13.02% lower.
P/B
Median3y
7.80
Median5y
6.85
FCF Yield
Median3y
3.74
Median5y
4.67
Competitors Valuation Multiple
AI Analysis for CORT
The average P/S ratio for CORT competitors is 231.52, providing a benchmark for relative valuation. Corcept Therapeutics Inc Corp (CORT.O) exhibits a P/S ratio of 4.24, which is -98.17% above the industry average. Given its robust revenue growth of 13.75%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for CORT
1Y
3Y
5Y
Market capitalization of CORT increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of CORT in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is CORT currently overvalued or undervalued?
Corcept Therapeutics Inc (CORT) is now in the Overvalued zone, suggesting that its current forward PE ratio of 71.90 is considered Overvalued compared with the five-year average of 34.86. The fair price of Corcept Therapeutics Inc (CORT) is between 9.86 to 28.86 according to relative valuation methord. Compared to the current price of 36.74 USD , Corcept Therapeutics Inc is Overvalued By 27.29% .
What is Corcept Therapeutics Inc (CORT) fair value?
CORT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Corcept Therapeutics Inc (CORT) is between 9.86 to 28.86 according to relative valuation methord.
How does CORT's valuation metrics compare to the industry average?
The average P/S ratio for CORT's competitors is 231.52, providing a benchmark for relative valuation. Corcept Therapeutics Inc Corp (CORT) exhibits a P/S ratio of 4.24, which is -98.17% above the industry average. Given its robust revenue growth of 13.75%, this premium appears unsustainable.
What is the current P/B ratio for Corcept Therapeutics Inc (CORT) as of Jan 09 2026?
As of Jan 09 2026, Corcept Therapeutics Inc (CORT) has a P/B ratio of 6.35. This indicates that the market values CORT at 6.35 times its book value.
What is the current FCF Yield for Corcept Therapeutics Inc (CORT) as of Jan 09 2026?
As of Jan 09 2026, Corcept Therapeutics Inc (CORT) has a FCF Yield of 4.06%. This means that for every dollar of Corcept Therapeutics Inc’s market capitalization, the company generates 4.06 cents in free cash flow.
What is the current Forward P/E ratio for Corcept Therapeutics Inc (CORT) as of Jan 09 2026?
As of Jan 09 2026, Corcept Therapeutics Inc (CORT) has a Forward P/E ratio of 71.90. This means the market is willing to pay $71.90 for every dollar of Corcept Therapeutics Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Corcept Therapeutics Inc (CORT) as of Jan 09 2026?
As of Jan 09 2026, Corcept Therapeutics Inc (CORT) has a Forward P/S ratio of 4.24. This means the market is valuing CORT at $4.24 for every dollar of expected revenue over the next 12 months.